Claims
- 1. A compound having the structure Ia, ##STR234## or a stereoisomer thereof, wherein n is 0, 1 or 2; R.sub.b is --A.sup.1 --R.sup.3a, --CO--A.sup.1 --R.sup.3a or --SO.sub.2 --A.sup.1 --R.sup.3a ;
- wherein R.sup.3a is guanidine, amidine or amino, and A.sup.1 is an alkyl, alkenyl or alkynyl chain of 2 to 6 carbons, provided that where R.sub.b is --A.sup.1 --R.sup.3a, A.sup.1 is an alkenyl or alkynyl chain of 2 to 6 carbons; or
- R.sub.b is --(CH.sub.2).sub.p --A.sup.2 --R.sup.2' or --(C.sub.2).sub.p --CO--A.sup.2 R.sup.2' where p is 0, 1 or 2, R.sup.2' is amidine and A.sup.2 is an azacycloalkyl, azaheteroalkyl or azaheteroalkenyl ring of 4 to 8 atoms, optionally substituted by alkyl, CO or halo as given by the structure: ##STR235## where X' is CH.sub.2, O, S or NH; p is 0, 1 or 2;
- q=0, 1, 2, 3 or 4 if X'.dbd.CH.sub.2 ;
- q=2,3 or 4 if X'.dbd.O, S, NH; and
- y.sup.1, y.sup.2 are independently H, alkyl or halo; or
- R.sub.b is --(CH.sub.2).sub.p --A.sup.3 --R.sup.4, --(CH.sub.2).sub.p --CO--A.sup.3 --R.sup.4, or --(CH.sub.2).sub.p --SO.sub.2 --A.sup.3 --R.sup.4,
- wherein R.sup.4 is guanidine, amidine or aminomethyl, and A.sup.3 is aryl or cycloalkyl;
- R is hydrogen, hydroxyalkyl, aminoalkyl, alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amidoalkyl, arylalkoxyalkyl or an amino acid side chain, either protected or unprotected;
- R.sup.1 and R.sup.2 are independently hydrogen, lower alkyl, cycloalkyl, aryl, hydroxy, alkoxy, oxo, thioxo, thioalkyl, thioaryl, amino or alkylamino;
- R.sup.6 is hydrogen, ##STR236## --SO.sub.2 R.sup.7' or --CO.sub.2 R.sup.7' (wherein R.sup.7' is lower alkyl, aryl or cyclohetero-alkyl);
- or a pharmaceutically acceptable salt thereof.
- 2. A method of inhibiting or preventing formation of blood clots, which comprises administering to a patient in need of treatment a antithrombin effective amount of a compound as defined in claim 1.
- 3. A pharmaceutical composition comprising a antithrombin effective amount of a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.
- 4. The compound as defined in claim 1 having the structure Ia, ##STR237## or a stereoisomer thereof, wherein n is 0, 1 or 2; R.sub.b is --(CH.sub.2).sub.p --A.sup.2 --A.sup.2' or --(CH.sub.2).sub.p --CO--A.sup.2 R.sup.2' where p is 0, 1 or 2, R.sup.2' is amidine and A.sup.2 is an azacycloalkyl, azaheteroalkyl or azaheteroalkenyl ring of 4 to 8 atoms, optionally substituted by alkyl, CO or halo as given by the structure: ##STR238## where X' is CH.sub.2, O, S or NH; p is 0, 1 or 2;
- q=0, 1, 2, 3 or 4 if X'.dbd.CH.sub.2 ;
- q=2,3 or 4 if X'.dbd.O, S, NH; and
- y.sup.1, y.sup.2 are independently H, alkyl, or halo;
- R.sup.1 and R.sup.2 are independently hydrogen, lower alkyl, cycloalkyl, aryl, hydroxy, alkoxy, keto, thioketal, thioalkyl, thioaryl, amino or alkylamino;
- R is hydrogen, hydroxyalkyl, aminoalkyl, alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amidoalkyl, arylalkoxyalkyl or an amino acid side chain, either protected or unprotected; and
- R.sup.6 is hydrogen, ##STR239## --SO.sub.2 R.sup.7' or --CO.sub.2 R.sup.7' (wherein R.sup.7' is lower alkyl, aryl or cyclohetero-alkyl);
- or a pharmaceutically acceptable salt thereof.
- 5. The compound as defined in claim 4 wherein n is O, R.sup.6 is 2-naphthylsulfonyl, H, methyl-sulfonyl, benzyloxycarbonyl or t-butoxycarbonyl, R is arylalkyl, hydroxyalkyl or benzyloxyalkyl, R.sup.1 is H, R.sup.2 is H and R.sub.b is ##STR240##
- 6. The compound as defined in claim 1 wherein R.sub.b is --A.sup.1 --R.sup.3a, ##STR241## or --SO.sub.2 --A.sup.1 --R.sup.3 a.
- 7. The compound as defined in claim 1 wherein R.sub.b is --(CH.sub.2).sub.p --A.sup.2 --R.sup.2' or ##STR242##
- 8. The compound as defined in claim 1 wherein R.sub.b is --(CH.sub.2).sub.p --A.sup.3 --R.sup.4, --(CH.sub.2).sub.p --CO--A.sup.3 --R.sup.4 or --(CH.sub.2).sub.p --SO.sub.2 --A.sup.3 --R.sup.4.
- 9. The compound as defined in claim 1 wherein n is O.
- 10. The compound as defined in claim 1 wherein R.sup.6 is 2-naphthylsulfonyl, H, benzyloxycarbonyl, t-butoxycarbonyl or methylsulfonyl.
- 11. The compound as defined in claim 1 wherein R.sup.3a is guanidine or amino.
- 12. The compound as defined in claim 1 having the structure ##STR243##
- 13. The compound as defined in claim 1 which is �S-(R* R*)!-4-�(aminoiminomethyl)amino!-N-��1-�3-hydroxy-2-�(2-naphthalenylsulfonyl)amino!-1-oxoprop-yl!-2-pyrrolidinyl!-METHYL!butanamide, or a pharmaceutically acceptable salt thereof;
- �R-(R*,S*)!-4-�(aminoiminomethyl)amino!-N-��1-(2-amino-1-oxo-3-phenylpropyl)-2-pyrrolidinyl!-methyl!butanesulfonamide, or a pharmaceutically acceptable salt thereof;
- �R-(R*,S*)!-�2-�2-����3-�(aminoiminomethyl)-amino!propyl!sulfonyl!amino!methyl!-1-pyrrolidinyl-2-oxo-1-(phenylmethyl)ethyl!carbamic acid, 1,1-dimethylethyl ester or a pharmaceutically acceptable salt thereof;
- �R-(R*,S*)!-3-�(aminoiminomethyl)amino!-N-��1-(2-amino-1-oxo-3-phenylpropyl)-2-pyrrolidinyl!-methyl!propanesulfonamide, or a pharmaceutically acceptable salts thereof;
- �R-(R*,S*)!-2-amino-1-�2-���4-(aminomethyl)-phenyl!-amino!METHYL!-1-pyrrolidinyl!-3-phenyl-1-propanone, or a pharmaceutically acceptable salt thereof;
- �R-(R*,S*)!-N-�2-�2-���4-(aminomethyl)phenyl!amino!METHYL!-1-pyrrolidinyl!-2-oxo-1-(phenylmethyl)-ethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,S*)!-4-�(aminoiminomethyl)amino!-N-��1-�2-�(methylsulfonyl)amino!-1-oxo-3-phenylpropyl!-2-pyrrolidinyl!methyl!butanamide, or a pharmaceutically acceptable salt thereof;
- �R-(R*,S*)!-2-amino-1-�2-���4-(aminomethyl)-phenyl!amino!METHYL!-1-pyrrolidinyl!-3-phenyl-1-propanone, or a pharmaceutically acceptable salt thereof;
- �R-(R*,S*)!-N-�2-�2-���4-(aminomethyl)phenyl!amino!METHYL!-1-pyrrolidinyl!-2-oxo-1-(phenylmethyl)ethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,R*)!-4-�(aminoiminomethyl)amino!-N-��1-�3-hydroxy-2-��(7-methoxy-2-naphthalenyl)sulfonyl!amino!-1-oxopropyl!-2-pyrrolidinyl!methyl!butanamide, or a pharmaceutically acceptable salt thereof;
- �R-(R*,S*)!-N-�2-�2-���4-(aminoiminomethyl)-phenyl!amino!METHYL!pyrrolidinyl!-2-oxo-1-(phenylmethyl)ethyl!methanesulfonamide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,S*)!-4-���1-(2-amino-1-oxo-3-phenyl-propyl)-2-pyrrolidinyl!METHYL!amino!benzenecarbox-imidamide, or a pharmaceutically acceptable salt thereof;
- �R-(R*,S*)!-N-�2-�2-���4-(aminoiminomethyl)phenyl!amino!methyl!pyrrolidinyl!-2-oxo-1-(phenylmethyl)ethyl!methanesulfonamide, or a pharmaceutically acceptable salt thereof;
- �1(S),2S!-1-(aminoiminomethyl)-N-��1-�3-hydroxy-2-�(2-naphthalenylsulfonyl)amino!-1-oxo-propyl!-2-pyrrolidinyl!methyl!-3-piperidinecarboxamide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,R*)!-1-(aminoiminomethyl)-N-��1-�3-hydroxy-2-�(2-naphthalenylsulfonyl)amino!-1-oxopropyl!-2-pyrrolidinyl!methyl!-4-piperidinecarboxamide, or a pharmaceutically acceptable salt thereof;
- N-�(S)-2-�(S)-2-����1-(aminoiminomethyl)-3-piperidinyl!acetyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,R*)-N-�2-�2-����1-(aminoiminomethyl)-4-piperidinyl!acetyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt;
- �S (R*,R*)!-N-�2-�2-���5-�(aminoiminomethyl)amino!-1-oxopentyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonarnide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,R*)!-N-�2-�2-���6-�(aminoiminomethyl)amino!-1-oxohexyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �1S�2R*(3S*)!!-N-�2-�2-����1-(aminoimino-methyl)-3-piperidinyl!carbonyl!amino!methl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,R*)!-N-�2-�2-���7-�(aminoiminomethyl)amino!-1-oxoheptyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �1S�2R*(3R*)!!-N-�2-�2-����1-aminoimino-methyl)-3-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, acceptable salt thereof;
- �S-(R*,R*)!-4-(aminomethyl)-N-��1-�3-hydroxy-2-�(2-naphthalenylsulfonyl)amino!-1-oxopropyl!-2-pyrrolidinyl!methyl!benzamide, or a pharmaceutically acceptable salt thereof;
- �1S(2R*,3R*)!-N-�2-����1-(aminoiminomethyl)-3-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-.alpha.-toluenesulfonamide or a pharmaceutically acceptable salt thereof:
- �1S(2R*,3R*)!-N-�2-����1-(aminoiminomethyl)-3-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(carbomethoxymethyl)-2-oxoethyl-.alpha.-toluenesulfonamide or a pharmaceutically acceptable salt thereof;
- �1S(2R*,3R*)!-N-�2-����1-(aminoiminomethyl)-3-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(carboxamidomethyl)-2-oxoethyl!-.alpha.-toluenesulfonamide or a pharmaceutically acceptable salt thereof;
- S-(R*,R*)!-3-(aminomethyl)-N-��1-�3-hydroxy-2-�(2-napthalenylsulfonyl)amino!-1-oxopropyl!-2-pyrrolidinyl!methyl!benzamide, or a pharmaceutically acceptable salt thereof;
- S-(R*,R*)!-4-(aminomethyl)-N-��1-�3-hydroxy-2-�(2-napthalenylsulfonyl)amino!-1-oxopropyl!-2-pyrrolidinyl!methyl!benzeneacetamide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,R*)!-3-(aminomethyl)-N-��1-�3-hydroxy-2-�(2-napthalenylsulfonyl)amino!-1-oxopropyl!-2-pyrrolidinyl!methyl!benzeneacetamide, or a pharmaceutically acceptable salt thereof;
- �3S-�3R*,3(R*,R*)!!-1-(aminoiminomethyl)-N-��1-�2-�(2-napthalenylsulfonyl)amino!-1-oxopropyl1!-2-pyrrolidinyl!methyl!-3-piperidinecarboxamide, or a pharmaceutically acceptable salt thereof;
- �3S-�3R*,3(R*,R*)!!-1-(aminoiminomethyl)-N-��1-�3-hydroxy-2-��(4-methylphenyl)sulfonyl!amino!-1-oxopropyl!-2-pyrrolidinyl!METHYL!-3-piperidinecarboxamide, or a pharmaceutically acceptable salt thereof:
- �3S-�3R*,3(R*,R*)!!-1-(aminoiminomethyl)-N-��1-�3-hydroxy-2-��carbobenzyloxy!amino!-1-oxopropyl!-2-pyrrolidinyl!methyl!-3-piperidinecarboxamide, or a pharmaceutically acceptable salt thereof;
- �1S�2(R*,S*)!!-N-�2-����1-aminoiminomethyl)-4-piperidinyl!carbonyl!amino!methyl!-1-piperidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,R*)!-3-�(aminoiminomethyl)amino!-N-��1-�3-hydroxy-2-��2-naphthalenesulfonyl!amino!-1-oxopropyl!-2-pyrrolidinyl!methyl!propionamide, or a pharmaceutically acceptable salt thereof;
- �1S�2(R*,S*),(3R*)!!-N-�2-����1-(aminoimino-methyl)-3-piperidinyl!carbonyl!amino!methyl!-1-piperidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �1S�2R*!!-N-�2-����1-(aminoiminomethyl)-3-phenyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �1S�2R*!!-N-�2-����1-(aminoiminomethyl)-cis-5-methyl-3-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �1S�2R*!!-N-�2-����1-(aminoiminomethyl)-trans-5-methyl-3-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(hydroxymethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �1S(2R*,3R*,4R*)!-N-�2-����1-(aminoiminomethyl)-3-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(1-hydroxyethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt;
- �1S(2R*,3S*,4R*)!-N-�2-���1-(aminoiminomethyl)-3-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(1-hydroxyethyl)-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �R-(S*,R*)!-N-�2-�2-����1-(aminoiminomethyl)-4-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(phenylmethyl)-2-oxoethyl!methanesulfonamide, or a pharmaceutically acceptable salt thereof;
- �S-(R*,R*)!-N-�2-����1-(aminoiminomethyl)-3-piperidinyl!carbonyl!amino!methyl-1-pyrrolidinyl!-2-oxoethyl!-2-naphthalenesulfonamide, or a pharmaceutically acceptable salt thereof;
- �R-(S*,R*)!-N-�2-�2-����1-(aminoiminomethyl)-4-piperidinyl!carbonyl!amino!methyl!-1-pyrrolidinyl!-1-(methyl)-2-oxoethyl!benzylsulfonamide, or a pharmaceutically acceptable salt thereof; ##STR244## or a pharmaceutically acceptable salt thereof; ##STR245## or a pharmaceutically acceptable salt thereof; ##STR246## or a pharmaceutically acceptable salt thereof; ##STR247## or a pharmaceutically acceptable salt thereof; ##STR248## or a pharmaceutically acceptable salt thereof; ##STR249## or a pharmaceutically acceptable salt thereof.
- 14. A compound according to claim 13 wherein the pharmaceutically acceptable salt is a trifluoroacetate.
REFERENCE TO OTHER APPLICATIONS
This is a division of application Ser. No. 373,334, filed Jan. 17, 1995, now U.S. Pat. No. 5,583,146 which is a continuation-in-part of application Ser. No. 146,714 filed Nov. 10, 1993, now abandoned, which is a continuation-in-part of application Ser. No. 112,153 filed Aug. 26, 1993, now abandoned, which is a continuation-in-part of application Ser. No. 984,640 filed Dec. 2, 1992, now abandoned. Application Ser. No. 373,334 is also a continuation-in-part of application Ser. No. 207,725 filed Mar. 14, 1994now abandoned; which is a continuation-in-part of application Ser. No. 56,279 filed May 3, 1993, now abandoned; and a continuation-in-part of application Ser. No. 207,726 filed Mar. 14, 1994, now abandoned, which is a continuation-in-part of application Ser. No. 56,017 filed May 3, 1993, now abandoned, and a continuation-in-part of application Ser. No. 112,155 filed Aug. 26, 1993, now abandoned, and a continuation-in-part of application Ser. No. 213,964 filed Mar. 16, 1994.
US Referenced Citations (8)
Foreign Referenced Citations (5)
Number |
Date |
Country |
479489 |
Apr 1992 |
EPX |
526877 |
Feb 1993 |
EPX |
0669317 |
Mar 1995 |
EPX |
WO931115 |
Jun 1993 |
WOX |
WO9429336 |
Dec 1994 |
WOX |
Non-Patent Literature Citations (13)
Entry |
Stuerzebecher J. Markwardt F, Walsmann P, Voigt B, Wagner G. Pharmazie, 42(2), 114-16, 1987. |
Rubini E, Gilon C, Selinger Z, Chorer M. Tetrahedron 42(21), 6039-45, 1986. |
Robert M. Knabb et al, "In Vivo Characterization of a New Synthetic Thrombin Inhibitor," Thrombosis and Hemostasis (1992) 67, 56-59. |
Charles V. Jackson et al, "Pharmacological Assessment of the Antithrombotic Activity of the Peptide Thrombin Inhibitor, D-Methyl-Phenylalanyl-Prolyl-Arginal (GYKI-14766), in a Canine Model of Coronary Artery Thrombosis," J. Pharm. Exp. Ther. (1992) 261, 546-552. |
Greissbach, U. et al "Peptide aldehydes as inhibitors of proteolytic enzymes-synthetic aspects"CA102:181323a (1983). |
Shuman, R.T. et al "Highly Selective Tripeptide Thrombin Inhibitors" J. Med. Chem. 36, 314-19 (1993). |
Bajusz, S. et al "Highly Active and Selective Anticoagulants" J. Med. Chem. 33, 1729-35 (1990). |
Rubini, E. et al "synthesis of Isosteric Methylene-oxy Pseudodipeptide Analogues as Novel Amide Bond Surrogate Units" Tetrahedron 42, 6039-45 (1986). |
Spatola, A.F. et al "Amide Bond Surrogates: Pseudopeptides and Macrocycles" Tetrahedron 44, 821-833 (1988). |
McOmie, J.F.W. Protective Groups in Organic Chemistry Plenum Press, p. 46, 55-57, 73 (1973). |
Banner, D. et al "Serine Proteases: 3D Structures, Mechanisms of Action and Inhibitors"Prospect. Med. Chem. Bernard (Ed), Verlag Publishing, p. 27-43 (1993). |
Hackh's Chemical Dictionary, McGraw-Hill, p. 16 (1982). |
Burger, A. "A Guide to the Chemical Basis of Drug Design" Wiley, Science, p. 15 (1984). |
Related Publications (4)
|
Number |
Date |
Country |
|
207725 |
Mar 1994 |
|
|
207726 |
Mar 1994 |
|
|
112155 |
Aug 1993 |
|
|
213964 |
Mar 1994 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
373334 |
Jan 1995 |
|
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
146714 |
Nov 1993 |
|
Parent |
112153 |
Aug 1993 |
|
Parent |
984640 |
Dec 1992 |
|
Parent |
056279 |
May 1993 |
|
Parent |
056017 |
May 1993 |
|